P
Philippe Pouletty
Researcher at Genzyme
Publications - 41
Citations - 1186
Philippe Pouletty is an academic researcher from Genzyme. The author has contributed to research in topics: Antibody & Transplantation. The author has an hindex of 18, co-authored 38 publications receiving 1166 citations. Previous affiliations of Philippe Pouletty include University of São Paulo.
Papers
More filters
Journal ArticleDOI
Results of the double-blind, randomized, multicenter, phase III clinical trial of thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation
Osama Gaber,M. Roy First,Raymond J. Tesi,Robert S. Gaston,Robert Mendez,Laura L. Mulloy,Jimmy A. Light,Lillian W. Gaber,E. C. Squiers,Rodney J. Taylor,John F. Neylan,Robert W. Steiner,Stuart J. Knechtle,Douglas J. Norman,Fuad S. Shihab,Giacomo Basadonna,Daniel C. Brennan,Ernest E. Hodge,Barry D. Kahan,Lawrence Kahana,Steven M. Steinberg,E. Steve Woodle,Laurence Chan,John M. Ham,Robert J. Stratta,Erik Wahlstrom,Kathleen R. Lamborn,H. Rossiter Horn,Hana Berger Moran,Philippe Pouletty,Timothy J. Schroeder +30 more
TL;DR: Thymoglobulin was found to be superior to Atgam in reversing acute rejection and preventing recurrent rejection after therapy in renal transplant recipients.
Patent
Liquid medication dispenser apparatus
Laurence R. Nicholson,Cliff Tyner,Debra L. Mcenroe,Britts Robert A,Philippe Pouletty,Levy Ralph +5 more
TL;DR: In this article, a liquid medication dispenser apparatus (10) is presented for user-friendly medication measurement and compliance, which can be downloaded to a personal computer (PC) for evaluation of patient compliance.
Journal ArticleDOI
Correlation of ELISA-detected IgG and IgA anti-HLA antibodies in pretransplant sera with renal allograft rejection
Ronald H. Kerman,B. Susskind,Roland Buelow,Jeffrey Regan,Philippe Pouletty,J. Williams,Kathy Gerolami,David H. Kerman,Stephen M. Katz,Charles T. Van Buren,Barry D. Kahan +10 more
TL;DR: The data suggest that the use of the ELISA methodology to detect IgG reactivity against soluble HLA class I antigens (PRA-STAT) may allow for the determination of a more clinically informative % PRA than the AHG-% PRA.
Patent
Cellular and serum protein anchors for modulating pharmacokinetics
TL;DR: In this paper, the authors provided a novel bifunctional reagents useful in reducing the biological effect of an undesirable blood-borne agent, such as growth factor, coagulation factor, enzyme, toxin, drug of abuse, microbe, autoreactive immune cell, infected or tumorous cell, where the anchor is a long-lived blood component.
Patent
Cellular and serum protein anchors and conjugates
TL;DR: In this paper, a bifunctional reagents useful in providing extended in vivo lifetimes of physiologically active agents are provided. The reagents comprise conjugates of a first binding member specific for a target in a mammalian host, such as a toxin, drug of abuse, microbe, autoreactive immune cell, infected or tumourous cell, antigen presenting cell, or the like, joined to a second binding member specifically for along-lived blood component, including cells, including an erythrocyte, platelet or endothelial cell, and plasma